APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 Russian patent published in 2017 - IPC A61K39/395 A61P35/00 

Abstract RU 2632108 C2

FIELD: medicine.

SUBSTANCE: method of treating a disease comprises administering to a human an immunoconjugate comprising at least one engineered targeting antibody targeted by cells expressing CD138 and at least one effector molecule, wherein said engineered targeting antibody is operably linked to said effector molecule to form mentioned immunoconjugate. A portion of the designed targeting antibody imparts IgG4 isotype characteristics, wherein the engineered targeting antibody comprises: (i) a heavy chain having at least 85% sequence identity with SEQ ID NO: 1, wherein the heavy chain comprises a variable region containing amino acid residues 31-35 (CDR1), 51-68 (CDR2) and 99-111 (CDR3) of SEQ ID NO: 1, and (ii) a light chain having at least 85% sequence identity with SEQ ID NO: 2, wherein the light chain comprises a variable A region containing amino acid residues 24-34 (CDR1), 50-56 (CDR2), and 89-97 (CDR3) of the sequence of SEQ ID NO: 2. The effector molecule is a maytansinoid. The immunoconjugate is administered in a cycle of active treatment lasting 21 days, at least three times within the indicated 21 days. The mentioned active treatment cycle comprises the mentioned administration, performed at least once a week, wherein the immunoconjugate is administered at least once a week at a dose of 80 mg/m2 Up to 120 mg/m2. The group of inventions also relates to a kit for treating a disease associated with target cells expressing CD138.

EFFECT: use of this group of inventions allows for the introduction of higher doses of immunoconjugate in a multiple-dose regimen with allowance for the limiting toxicity.

23 cl, 38 dwg, 24 tbl, 4 ex

Similar patents RU2632108C2

Title Year Author Number
APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET 2010
  • Osterrot Frank
  • Uehrek Kristof
  • Brjukher Kristof
  • Delken Benzhamin
  • Ehngling Andre
  • Kheder Tomas
  • Vartenberg-Demand Andrea
  • Nimann Gabriehle
  • Tsuber Shantal'
  • Chelot Niklas
  • Ajgner Zil'Ke
  • Tseng Shteffen
  • Shul'Ts Gregor
RU2561041C2
ANTI-CD138 IMMUNOCONJUGATES AND USING THEM 2008
  • Kraus, Ehl'Mar
  • Brjukher, Kristof
  • Delken, Benzhamin
  • Tseng, Shteffen
  • Osterrot, Frank
  • Uehrek, Kristof
  • Ajgner, Zil'Ke
  • Germer, Mattias
RU2547939C2
METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT 2008
  • Delken Benzhamin
  • Uehrek Kristof
  • Anderson Kennet
  • Khidesima Teru
  • Brjukher Kristof
RU2486203C2
CD138-TARGETED CELL AGENTS AND USING THEM 2008
  • Kraus,Ehl'Mar
  • Brjukher,Kristof
  • Delken,Benzhamin
  • Germer,Mattias
  • Tseng,Shteffen
  • Osterrot,Frank
  • Uehrek,Kristof
  • Ajgner,Zil'Ke
  • Shul'Ts,Gregor
RU2537265C2
NEW SYNERGETIC EFFECTS 2009
  • Lutts Robert Dzh.
  • Uajtmehn Kehtlin R.
RU2471499C2
ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF 2010
  • Kanert, Ant'E
  • Berkherster, Kerstin
  • Khajsler, Iring
  • Kopitts, Sharlotte Kristine
  • Shumakher, Joakhim
RU2575612C2
COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART 2008
  • Neri Dario
  • Menssen Khans Ditrikh
  • Menrad Andreas
  • Shliman Kristof
RU2484845C2
THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) 2017
  • Govindan Serengulam V.
  • Goldenberg David M.
RU2757395C2
HETEROMULTIMERIC PROTEINS PRODUCTION 2011
  • Sheer Dzhastin
  • Shpiss Kristof
  • Yansura Deniel Dzh.
RU2624027C2
TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR 2018
  • Cardillo Thomas M.
  • Goldenberg David M.
RU2758234C2

RU 2 632 108 C2

Authors

Shults Gregor

Osterrot Frank

Kheder Tomas

Bryukher Kristof

Nimann Gabriele

Engling Andre

Uerek Kristof

Delken Benzhamin

Vartenberg-Demand Andrea

Tsuber Shantal

Gucher Markus

Bernester Katrin

Kenig Martin

Dates

2017-10-02Published

2012-12-07Filed